Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 3/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | UBE2M | P61081 | 1/20 | 0.35 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31478849 | 1.00 | OPRK1 (0.43) | OPRK1SLC6A4SLC6A3TAS1R3TAS1R1 | |
| SCHEMBL9100354 | 1.00 | OPRK1 (0.43) | OPRK1SLC6A4SLC6A3TAS1R3TAS1R1 | |
| SCHEMBL9103917 | 0.94 | OPRK1 (0.42) | OPRK1SLC6A4SLC6A3TAS1R3TAS1R1 | |
| SCHEMBL9099303 | 0.94 | OPRK1 (0.42) | OPRK1SLC6A4SLC6A3TAS1R3TAS1R1 | |
| SCHEMBL9105962 | 0.90 | OPRK1 (0.37) | OPRK1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL9104979 | 0.90 | OPRK1 (0.37) | OPRK1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL31478912 | 0.90 | OPRK1 (0.37) | OPRK1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL9102284 | 0.88 | OPRK1 (0.36) | OPRK1SLC6A4MAOAMAOB | |
| SCHEMBL9102296 | 0.88 | OPRK1 (0.36) | OPRK1SLC6A4MAOAMAOB | |
| SCHEMBL9100511 | 0.87 | KDM2B (0.39) | OPRK1SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8361998-B2 | Compounds and their use as IKACh blockers | ASTRAZENECA AB | 2013-01-29 | — | — | US | claimed |
| WO-2012074469-A1 | NEW IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | WO | claimed |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | claimed |
| US-20130143858-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2013-06-06 | — | — | US | disclosed |
| US-8361998-B2 | Compounds and their use as IKACh blockers | ASTRAZENECA AB | 2013-01-29 | — | — | US | disclosed |
| WO-2012074469-A1 | NEW IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143858-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | OPRK1 398/4885SLC6A4 1410/4885SLC6A3 1421/4885 |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | OPRK1 398/4885SLC6A4 1410/4885SLC6A3 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.